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Background: Despite a higher prevalence of depression among HIV-infected veterans, 
previous research has shown that infectious disease (ID) providers report substantially 
less comfort with depression treatment than do general medicine (GM) providers. We 
examined whether HIV-infected veterans who are treated by ID providers are less likely 
to have their depressive symptoms treated compared to uninfected controls managed by 
GM providers. 
 
Methods: We used survey, service utilization, and pharmacy data on veterans from the 
Veterans Aging Cohort Study (VACS), a prospective cohort study of HIV-infected and 
age-, race- and site-matched uninfected subjects at 8 Veterans Affairs Healthcare Centers.  
We used the Patient Health Questionnaire (PHQ-9) to identify veterans with depressive 
symptoms. Each of nine survey items was rated by the veteran as being present "0" (not 
at all) to "3" (nearly every day). Veterans were considered to have active depressive 
symptoms if they had a PHQ-9 score of 10 or greater, which constituted a positive screen 
for major depressive disorder.  Of the 5998 VACS patients, 19.7% of uninfected and 
21.3% of HIV-infected veterans had PHQ-9 scores of 10 or greater.  Of these veterans 
with active depressive symptoms, those receiving mono-amine oxidase inhibitors 
(MAOIs) (n=3), female veterans, and men with diagnoses of schizophrenia (n=511) or 
PTSD (n=689), were excluded.  A small number of patients receiving tricyclic 
antidepressants (TCAs) were excluded for criteria other than TCA use.  Depression 
treatment was defined as receipt of a selective serotonin reuptake inhibitor (SSRI) or any 
VA mental health utilization in the 6 months prior to or after survey.  Bivariate 
comparisons by clinic type were assessed using chi-square and t-tests. Logistic regression 
was used to determine whether clinic type was associated with receipt of SSRI, adjusting 
for potential confounding variables such as demographics and clinical factors.   
 
Results: Of the 5998 veterans in VACS, 732 met our criteria with PHQ-9 scores greater 
than 10, male gender, without schizophrenia, PTSD or MAOI use.  Of the 732 eligible 
veterans, 59% were HIV-infected and 41% were uninfected. The sample was 
predominantly African-American (58%) and had a median age of 48 years. There was no 
significant difference in the proportion of veterans with depressive symptoms who were 
treated by HIV status (38% of HIV-infected veterans vs. 34% of uninfected veterans, 
p=0.4). This remained true even when mental health service utilization was included 
(48% vs. 49%, p=0.8). Caucasian veterans were significantly more likely than African-
Americans to have received SSRI (48% vs. 30%, p<0.01).  After controlling for veteran 
age, race, and comorbid conditions, HIV-infected veterans did not differ significantly in 
receipt of SSRI (OR=1.16, 95% CI=0.84, 1.58).  However, there were significant 
differences in treatment rates by site and by individual clinic. 
 
Conclusions: Despite previous analysis demonstrating substantial differences in provider 
comfort with depression treatment, both HIV-infected and uninfected veterans were 
equally unlikely to be treated for depressive symptoms. While treatment rates did not 
vary by HIV status, they varied significantly by geographic site and individual clinic, 
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This thesis examines a specific general medical condition – depression – and its 
treatment in two primary care populations: HIV-infected and uninfected matched 
veterans.  Primary care physicians (PCPs) have taken responsibility for screening and 
treating uncomplicated depression.  Yet, based on lower provider-reported comfort with 
depression treatment by Fultz et al (2006) between general PCPs and HIV PCPs, we have 
reason to believe that depression may be less aggressively managed in HIV primary care 
than it is in general medical primary care (1).  Thus, with this study, we examine whether 
HIV status correlates with a difference in treatment of self-reported depressive symptoms 
among HIV-infected and uninfected veterans by their primary care providers. 
 
Depression Treatment is Valuable on a Societal and Personal Level 
Many researchers argue that all depression should be treated because of its staggering 
indirect costs to society.  In its “Global Burden of Disease Study,” the World Health 
Organization (WHO) predicts that depression will be the second leading cause of 
disability in the developed world by 2010 (2).  It cites depression as the leading cause of 
years lived with disability and the fourth leading cause of burden among all diseases (2).  
Depression incurs innumerable societal costs, including decreased productivity from 
missed work days and increased use of health services (3).  Health care costs for 
depressed older adults are more than 50% higher than for older adults without depression 
(4).   
On a personal level, depression affects medical outcomes, quality-of-life and 




motivation and altered concentration can lead to poor compliance with medical treatment 
plans (6).  There is evidence to suggest that depression can directly worsen medical 
illness, for instance by dysregulating neurohumoral pathways and increasing platelet 
activation in veterans with ischemic heart disease (7).  Depression treatment can improve 
quality of life and functioning, even in adults with complex chronic medical disease (4).    
Moreover, depression treatment can enhance self-management skills and enable patients 
to comply with complicated medical treatment regimens (8). 
 
Depression is Widespread, but Underdiagnosed and Undertreated 
Current literature describes depression as significantly underdiagnosed and undertreated 
(4;5;8;9).  In a primary care setting, depression point prevalence can be as high as 10-
14% (8).  Robert Wood Johnson Foundation’s “Depression in Primary Care” cites that 
only 50% of cardiac and diabetic patients with major depression are diagnosed and only 
25% of those diagnosed receive treatment (8).  Some researchers estimate that 30-70% of 
patients with major depression go undetected and less than 50% of primary care patients 
who are diagnosed receive appropriate treatment (9;10).  These statistics suggest that the 
current individualized approach to depression diagnosis and treatment does not work very 
well.  Many policymakers conclude that depression’s high prevalence coupled with low 
rates of diagnosis and treatment call for population-based approaches (5;8;9;11). 
 
Depression Treatment: Three Phases 
Defining depression treatment is not straightforward because there are multiple treatment 
modalities and phases.  Clinicians can choose from both antidepressants and 




In many of the treatment models, antidepressant medications are first-line 
treatment (4;5;9;13-15).  It is estimated that for those patients who respond to 
antidepressants, 20-40% respond to active treatment, 30% to placebo effect and the rest 
to spontaneous remission of depressive symptoms (5).  Antidepressant study attritionrates 
generally approach 30-40% and approximately 10-20% of patients drop out secondary to 
drug side effects (5).  Researchers attribute the remaining drop-outs to patient and 
provider factors.  Patients may have unrealistic treatment expectations, ambivalence and 
access issues (12).  Providers may neglect to follow through and adjust medication dosing 
and type as needed to reach treatment goals (12). 
Other treatment options include depression psychotherapy or combined therapy.  
Depression psychotherapy (including cognitive behavioral therapy, problem solving 
therapy and interpersonal psychotherapy) is clinically effective but not cost-effective 
(16).  Depression psychotherapy plus antidepressants is the clinical gold-standard therapy 
(16).  Unfortunately, as a society, we simply do not have enough manpower to offer 
psychotherapy to approximately 1 in 10 primary care patients estimated to have 
depression (17). 
US Preventive Services Task Force and institutions such as the Veterans Health 
Administration recommend antidepressants as first-line treatment due to their short-term 
cost-effectiveness and fewer demands for human resources (9;18).  Clinical research has 
determined that antidepressants are equally as effective as psychotherapy in treating acute 
episodes, inducing remission and preventing recurrence (5). 
Beyond the multiple treatment modalities, current treatment recommendations 
describe 3 potential phases of treatment: acute, continuation and maintenance.  The acute 




or both, and typically lasts 6-8 weeks (5).  The goal of this phase of treatment is to 
decrease a patient’s depressive symptoms by 50% or more.  Thus, the patient will no 
longer meet criteria for major depressive disorder. 
The second phase of treatment is the continuation phase.  Again, the options for 
treatment include antidepressant therapy, psychotherapy or both.  Continuation phase is 
defined as 6 months of continued antidepressants with biweekly or monthly physician 
follow-up (5).  The goal of continuation phase is to induce the patient’s depression into 
complete remission to prevent relapse.  Continuation treatment has been found to 
decrease relapse rates from 40-60% to 10-20% (5).   
 Finally, many patients require a maintenance phase of treatment to prevent 
recurrence of major depressive episodes.  For maintenance therapy, providers may 
continue antidepressants or monthly or quarterly physician follow-ups (5).  Maintenance 
therapy is recommended for patients with a history of 3 or more major depressive 
episodes, chronic depression or bipolar disorder (5;6).   
A significant proportion of patients eventually require long-term depression 
maintenance therapy.  Between 50-85% of those presenting with MDD will go on to have 
at least one lifetime recurrence, and a high proportion of these patients will require 
chronic maintenance therapy (19).  Thus, when starting a patient on depression treatment, 
whether medication or psychotherapy, it is important to consider that many will continue 
to require that therapy for the rest of their lives. 
 
Cost of Depression Treatment is a Formidable Barrier to Depression Treatment 
The high cost of depression treatment affects how clinicians create treatment guidelines 




Though policymakers recommend increasing depression treatment rates, the significant 
cost of depression treatment limits our options.  Researchers must address the question of 
where resources should be directed to make the biggest impact on depression outcomes.  
First, they must decide which therapeutic approach has the highest cost-effectiveness.  
The actual cost of SSRIs for depression treatment can vary considerably, depending on 
formulation and duration of treatment (Table 1).  The figures in Table 1 are low 
estimates, derived by using the lowest recommended dose and the cheapest available 
formulation of each medication.   
 
Table 1.  Cost of SSRIs Depression TreatmentA 
SSRI (Formulation) 
Cost of Treatment  
Per Month 
Cost of Treatment  
Per Year Dosing 
    
Fluoxetine 
(generic capsule) 
$15.99 $199.88 20 mg daily 
Sertraline  
(Zoloft™ tablet) 
$75.99 $911.88 50 mg daily 
Paroxetine  
(Paxil™ tablet) 
$90.50 $1086.00 20 mg daily 
Fluvoxamine  
(generic tablet) 
$62.99 $755.88 100 mg daily 
Citalopram  
(Celexa™ tablet) 
$72.99 $875.88 20 mg daily 
Escitalopram 
(Lexapro™ tablet) 
$70.15 $841.80 10 mg daily 
   
 
A Prices taken from Up To Date “Drug Information” (20-25).  The lower end of the recommended dosing 




For veterans in the VA health system, pharmaceutical costs may not be important 
factors because medications cost them a low co-pay of approximately $8 per 30 day 
prescription (26).  However, these costs are important to the VA health system as a 




inbulk, they pay significant overall prices to pharmaceutical companies for antidepressant 
medication. 
A thorough discussion of depression treatment costs must address the significant 
profit that pharmaceutical companies make from current treatment recommendations.  As 
more patients are screened and diagnosed with depression, pharmaceutical companies 
benefit further from higher antidepressant sales. 
The issue of cost-effectiveness in depression treatment is not straightforward.  
Some policymakers argue that psychotherapy is cost-effective because it reduces 
hospitalization (16).  However, only 5-10% of major depressive episodes require 
hospitalization (2;5).  Others argue that antidepressants are more cost-effective because 
they do not require as many human resources (2).  It seems that neither psychotherapy 
nor antidepressant cost analyses can adequately account for the large subpopulation of 
depressed patients who require lifelong maintenance therapy.  With either treatment 
option, depression treatment for an estimated 10% of the American population for their 
entire adult lives would create astronomical healthcare costs.  While it is unclear which 
depression treatment option is most cost-effective, it is clear that both therapies are 
enormously expensive. 
 
Depression is Often Treated in Primary Care 
In the modern U.S. healthcare system, primary care physicians serve as “gatekeepers” of 
medical resources for the general public (11).  They assume responsibility for 
preventative medicine, seeking out common diseases before a patient may have reason to 
suspect that he has a health problem.  In this sense, primary care is the logical field to 




patient insight.  In a paper commissioned by the National Institute for Mental Health as 
part of their series, “Challenges for the 21st Century: Mental Health Services Research 
Conference,” Benjamin Druss explains that primary care has the benefit of “first contact, 
longitudinality, comprehensiveness and coordination” (11).  When individuals develop a 
medical problem, they first seek out the general knowledge offered by PCPs.  Once 
patients interface with the medical system, they can create longitudinal relationships with 
PCPs.  This relationship, in turn, contributes to better mental health care.  A study by 
Gulbrandsen et al in a Scandinavian population found a positive association between a 
provider’s knowledge of patients and provider detection of psychosocial problems (11).  
Thus, encouraging PCPs to address depression may enhance the rates of detection and 
treatment.  New collaborative models of depression treatment have created a “therapeutic 
alliance” between PCPs and specialists to improve patient outcomes (4). 
 
HIV Primary Care 
In the United States, the availability of effective highly active antiretrovirals (HAART) 
therapy encouraged the development of a burgeoning field of medicine – HIV primary 
care.  HAART increased the average lifespan after diagnosis of HIV-infected patients 
(27).  After HAART, it was possible to imagine a future in which HIV-infected patients 
would live long enough to face general age-related medical diseases like the uninfected 
population (27).  As HIV-infected patients aged, they addressed non-infectious medical 
issues such as cardiovascular disease, diabetes and depression with greater frequency.  
However, this special patient population required HIV treatment and prophylaxis too 
complex to be managed by most primary care physicians.  The U.S. Department of 




HIV patients; they recommended that generalists care for at least 50 HIV-infected 
patients to remain proficient in HIV care (1).  Indeed, many ID specialists have taken 
over the role of both HIV specialist and primary care physician for their HIV-infected 
patients.  This arrangement has become policy within the Veterans Health 
Administration.  The designated primary care physician for HIV-infected veterans is the 
physician who manages their HIV infection.  Thus, HIV care created a special 
circumstance in which many specialists assumed responsibility for primary medical care.  
This arrangement optimizes HIV care but has introduced questions as to specialists’ 
competency in general medical care, as discussed by Fultz et al (1). 
 
HIV and Depression 
Depression is an important issue for providers treating HIV-infected patients.  HIV-
infected patients are twice as likely to be diagnosed with depression compared to 
uninfected patients (28).  Untreated depression has been associated with poorer HIV-
related outcomes, such as shorter survival times and increased use of HIV-related 
hospital services (29;30).  Many recent studies have demonstrated that HIV-infected 
patients benefit from improved quality of life and HIV-specific outcomes by treating 
comorbid depression (6;28;31).  The evidence seems to clearly indicate that providers 
should identify which patients are depressed in order to treat their depression and 
improve their health outcomes.   
Yet, among patients with complex chronic disease like HIV, it is not 
straightforward to make a diagnosis of depression.  Within the HIV-infected population, 
it is difficult to target subpopulations for screening; the risk for depression does not 




universal depression screening for HIV-infected patients is recommended (28).  Yet, 
universal screening has uncertain benefit in HIV-infected populations because current 
screening and diagnostic tools have questionable accuracy in patient populations with 
chronic medical illness.  The American Psychiatric Association’s DSM-IV includes 
specific somatic symptoms included in its formal depression diagnostic criteria (32).  
These somatic symptoms, termed “neurovegetative,” are non-specific symptoms that can 
be attributed to either medical or psychiatric illness (Table 2) (6).  Clinicians try to 
distinguish between cognitive-affective and neurovegetative symptoms to clarify whether 
neurovegetative symptoms should be interpreted as worsening medical disease or 
overlying psychiatric disease. 
 
Table 2.  Distinguishing between Cognitive Affective and Neurovegetative 
Symptoms of DepressionA  
 
Cognitive-affective Symptoms Neurovegetative Symptoms 
Anhedonia Sleep change 
Depressed mood Fatigue 
Low self-esteem Appetite change 
Suicidality Concentration difficulty 
 Psychomotor change 
  
A These specific terms were referenced from Colibazzi et al (6). 
 
This distinction becomes especially important in patients with chronic medical 
illness like HIV.  In “Practice Guidelines for the Treatment of Psychiatric Disorders,” the 
American Psychiatric Association acknowledges that clinicians face a diagnostic 
dilemma in separating mood disorders that stem from HIV neuropathic effects from true 
psychiatric disorders (33).  Any number of HIV-related diseases and medications could 




HIV PCPs, there is no clear answer for how to discriminate between medical or 
psychiatric disease, or if this distinction is clinically important.  For HIV PCPs and 
generalists alike, depression remains a complex clinical entity to diagnose and treat. 
 
Is There a Difference in Quality of Primary Care by Generalists vs. Specialists? 
A tension has developed between specialists and generalists regarding responsibility and 
quality of care in patients with chronic medical disease.  Indeed, a study of medical care 
utilization patterns of elderly Washington State residents found that specialists play a 
large role in the outpatient care of elderly patients (34).  Over the 2-year study period, 
14.7% of the patients saw only specialists (34).  However, this study went further to 
determine that specialists were not assuming the role of primary care provider to these 
patients.  They only were addressing medical problems relevant to their specialty (34).  
With the fragmentation of the modern health care system, specialists are taking 
responsibility for a majority of outpatient care, but only addressing medical issues within 
their specialty field (34).  These findings likely can be applied to any patient population 
with complex chronic medical diseases, which give patients the opportunity to establish 
strong relationships with individual physicians.  
In the wake of this shift to outpatient specialty care, clinical researchers have 
compared the quality of care given by generalists versus specialists for given medical 
conditions.  They have investigated whether patients with a primary chronic medical 
condition receive better care from a specialist than a generalist.  Many studies of 
specialist fields such as cardiology, gastroenterology and infectious disease have 
demonstrated improved overall health outcomes by specialists (34;35).  However, others 




not account for practice environment, patient volume or provider experience (35;36).  
Furthermore, ecological studies have demonstrated lower mortality rates and more 
equitable distribution of health in populations with many primary care providers, 
compared to those with many specialists (35).  With the evidence at hand, it is unclear 
whether generalists or specialists provide better care for patients.  In any case, it is 
difficult to apply current evidence to our study population because our patients have 
multiple comorbidities which complicate the clinical picture. 
With this study, we endeavor to answer a different question.  We do not compare 
how generalists perform to a specialist treating something within his own field.  We 
compare how well specialists perform when treating general medical conditions that are 
not within their field of specialty.  We contrast how infectious disease providers treat 
depression – widely considered a general medical condition – compared to generalists 
(5;8).  We earlier discussed that specialists report lower comfort levels with treating 
general medical conditions, including depression.  We investigate if lower comfort levels 






STATEMENT OF HYPOTHESIS 
To investigate a potential explanation for why a large proportion of depressed patients 
remain untreated, this project investigates the role of HIV status.  This study assesses 
differences in depression treatment between HIV-infected and uninfected veterans with 
active symptoms of depression.  The incidence of depression itself has been demonstrated 
to be higher in HIV-infected veterans compared to uninfected veterans (28).  However, a 
prior paper by Fultz et al suggests that the overall proportion of HIV-infected veterans 
treated for depression may be lower than the proportion of uninfected veterans because 
HIV PCPs report lower comfort levels with treating depression than do general PCPs.  
Fultz reports a significant difference in HIV PCPs’ stated comfort levels with depression 
treatment (42%) compared to those of general medicine PCPs (79%).  Therefore, if HIV 
primary care providers feel less comfortable with treating depression, it seems likely that 
HIV-infected veterans with active depressive symptoms will have lower rates of 
depression treatment than their uninfected comparators.  Thus, this project will address 
the following question: what proportion of veterans who report depressive symptoms 
severe enough to screen positive for depression receive treatment and does this 
proportion differ by HIV status?   
 
Specifically, we will consider the following questions: 
1. Does the prevalence of active depressive symptoms vary by clinic type (which 
correlates directly with HIV status)? 
a. We hypothesize that the prevalence of veterans with active depressive 
symptoms will be higher in HIV-infected veterans compared to uninfected 
veterans. 
2. How does the provision of treatment, given the presence of active depressive 




a. We hypothesize that the provision of treatment, given the presence of 
active depressive symptoms, will be lower in HIV-infected veterans 
compared to uninfected veterans. 
3. What might explain potential differences in rates of depression treatment? 
a. Some variables considered: 
i. Veteran demographics 
1. Age 
2. Race 
3. Marital status 
ii. Medical comorbidities 
1. Substance abuse/dependence (alcohol and drug) 
2. Medical illnesses (cardiovascular, pulmonary, endocrine) 
iii. Geographic site 







The Veterans Aging Cohort Study (VACS) is a longitudinal prospective multi-center 
observational study conducted at the Veterans Health Administration.  This study 
compares HIV-infected veterans receiving care in infectious disease (ID) clinic and 
age/race/site-matched uninfected veterans receiving care in general medicine (GM) 
clinic.   
 
Veterans Health Administration 
The Veterans Health Administration (VA) is the largest integrated health care system in 
the U.S., which provides care to 3.6 million veterans annually (37).  It offers inpatient 
and outpatient general medical care as well as specialist care.  The system includes 
pharmacies, mental health services, substance abuse treatment programs, long-term care, 
rehabilitation services and homeless care.   
The VA is particularly suited to observational studies in populations with 
complex chronic disease (38).  Its veteran population has a high proportion of 
underrepresented veteran groups, including those with a high degree of frailty, low 
socioeconomic status, people of color and the elderly (38).  They also have a population 
of HIV-infected individuals who are, on average, 10 years older than the national 
average, as reported by the Center for Disease Control and Prevention (39).  These 
veteran populations, in particular, are important to study because they are poorly 
represented in clinical trials.  The VA system is large enough to assemble large cohorts 
with truly matched comparators.  Due to its sheer size, the VA cares for the nation’s 




nearly closed system, its records contain all health care utilization for its veterans.  
Moreover, most of its patients remain in the same system for their lifetime.  It provides a 
useful resource for clinical epidemiology with its nation-wide, fully-integrated electronic 
medical record (EMR) system.  Moreover, it is defined by a corporate culture which 
strives to exceed performance measures set by private health care corporations (39). 
 
Veterans Aging Cohort Study 
The VACS study includes patients at 8 Veterans Affairs Medical Center (VAMC) sites: 
Atlanta, Baltimore, Bronx, Houston, Los Angeles, New York, Pittsburgh, Washington, 
DC (39).   
The data included in this particular analysis was collected over a 2-year period 
from June 2002 to September 2004.  As of September 2004, VACS consented and 
enrolled 5,998 veterans (2979 HIV-infected, 3019 uninfected).  The study continues to 
enroll age/race/site matched comparators to replace those who have died or have been 
lost to follow-up.  Study protocols were approved by institutional review boards at all 
involved sites.  All study participants gave written informed consent. 
Trained study coordinators recruited HIV-infected veterans from infectious 
disease clinics and age/race/site-matched HIV-uninfected veterans from general medicine 
clinics.  Veterans were informed about the study, consented and then given a 
questionnaire to complete before leaving the clinic.  By consenting, subjects gave 
permission for study investigators to access their EMR information and to re-contact 
them in the future (39).   
 The VACS sample represented 99% of the VACS targets, including targets set for 




study.  This proportion was not significantly different by HIV status.  In all, VACS 
enrolled 58% of all HIV-infected veterans seen in infectious disease clinics at 
participating sites (39). 
In the short-term, this study aims to investigate outcomes associated with 
substance use, homelessness and medical and psychiatric disease in demographically-
comparable HIV-infected and uninfected veterans (38).  In the future, VACS 
investigators hope to use the data to create effective VA-wide programs based on risk 
assessments at a patient level and to prioritize health interventions (39). 
VACS primary funding sources include: National Institute on Alcohol Abuse and 
Alcoholism (3U01 AA 13566), National Institute of Aging (K23 AG00826), Robert 
Wood Johnson Generalist Faculty Scholar Award, an Inter-agency Agreement between 
National Institute on Aging, National Institute of Mental Health and the Veterans Health 
Administration, and the Veterans Health Administration Office of Research and 
Development and Public Health Strategic Health Care Group (39). 
 
Thesis Project 
This study is a secondary analysis of cross-sectional data collected by baseline survey for 
the VACS data set. 
 
Sample 
Veterans were recruited from general medicine and infectious disease primary care 
clinics at 8 diverse VA sites.  Veterans were compensated for their participation with $20 
cash, given to them upon completion of the questionnaire.  The VACS sample included 




score of 10 or greater (Figure 1).  Among the 5998, 19.74% of GM patients, and 21.25% 
of ID patients had a PHQ-9 score of 10 or greater (p=0.1483).  These veterans with active 
depressive symptoms were then excluded stepwise for the following criteria: female 
gender (n=316), diagnosis of schizophrenia (n=511) or PTSD (n=734) and MAOI use 
(n=2) (Figure 1).  From the initial VACS sample, 2250 veterans met inclusion criteria for 
our study.  Formal depression diagnosis was not taken into account as we wanted to 
include all patients with active depressive symptoms by our measure, whether or not they 
had been identified and diagnosed as such by their provider.  Female veterans were 
excluded because of their small number.  Those veterans with a diagnosis of 
schizophrenia were excluded as it is considered beyond the scope of primary care to treat 
depression comorbid with other complex psychiatric diagnoses.  Veterans with a 
diagnosis of PTSD were excluded because PTSD can potentially be treated with SSRIs 
and we would be unable to determine if a provider prescribed an SSRI to treat depression 
or PTSD (40;41).  As these psychiatric conditions are common within the veteran 
population, a large percentage of the male VACS subjects with PHQ-9 scores of 10 or 
greater were excluded for their psychiatric comorbidities.  Veterans receiving MAOIs 
(n=3) were excluded due to contraindications of co-receipt of MAOI and SSRI.  We 
considered excluding patients receiving TCAs from our sample because we would be 
unable to determine if patients received the medication for depression treatment or for 
another purpose, such as chronic pain treatment.  However, we did not need to address 
this issue because only a small number of veterans in this sample received TCAs and they 
were all excluded for reasons other than TCA use.  In total, 5267 (88%) of the original 










The final sample included 732 male veterans with depressive symptoms and no 
schizophrenia, PTSD or MAOI use.  Race/ethnicity was gathered from administrative 
data (39).  Veteran comorbidities were also determined from VA administrative data, and 
were grouped by categories.  A veteran was considered to have a comorbidity if he was 
assigned the ICD-9 code at any time in his care at the VHA, not just the 1-year time 
frame of this study.  The following categories included select conditions from the 
following ICD-9 codes (42): 
• Alcohol abuse/dependence: 291, 303, 305, 790, 980, E860 
VACS veterans 
N=5998 

























• Substance abuse/dependence: 292, 292, 304, 305, E855, E858 
• Coronary Artery Disease: 410-414, V45 
• Diabetes mellitus: 250, 357, 790-791 
• Hypertension: 401-405, 437 
• Pulmonary Disorder: 416, 490-493, 500-506, 518, 770 
 
These specific medical comorbidities were selected because of their association with high 
depression rates in recent literature (8).  The number of median and mean comorbid 
medical diseases was determined from VA administrative data.  In the HIV-infected 
population, the mean and median comorbid medical disease categories do not include 
their HIV diagnosis.  HIV severity measures (mean and median CD4 count, viral load) 
were determined from VA laboratory data, as part of the EMR. 
 
Data Collection 
Data sources used in this analysis included the following: veteran questionnaires, VA 
electronic medical record and national data sources. 
• Questionnaires were self-administered to each veteran.  The questionnaires were 
compiled using standardized survey instruments (39).  Many of the items were drawn 
from the national Veterans Health Survey, including questions for demographics, 
comorbidity, and healthcare utilization. 
• The VA Electronic Medical Record (EMR) was accessed for medical and 
administrative data, including health care utilization data and ICD-9 codes.  VA 
Computerized Veteran Record System (CPRS) provided demographic and clinical 
information such as laboratory data.  The Pharmacy Benefits Management (PBM) 






Quality control was ensured by a standardized site team, adherence to a Manual of 
Operations and regular contact between all sites. 
 
Measures 
Current depressive symptoms were evaluated using Patient Health Questionnaire-9 
(PHQ-9), a shortened version of PRIME-MD, a well-validated screening tool based on 
DSM-IV criteria for Major Depressive Disorder (MDD) (43).  PRIME-MD survey items 
were drawn directly from DSM-IV criteria, and divided into threshold and subthreshold 
categories to correspond with 18 psychiatric diagnoses, including MDD.  PHQ-9, a 
shortened version of the PRIME-MD which specifically addresses MDD, is valid for both 
criteria-based diagnosis and symptom severity evaluation (44).  It includes the following 
domains: anhedonia, depressed mood, sleep change, fatigue, appetite change, low self-
esteem, concentration difficulty, psychomotor change and suicidality (43).  PHQ-9 has 
proven to be an effective screen for MDD in clinical trials in special veteran populations, 
such as those with multiple comorbid medical illness and from various ethnic and cultural 
backgrounds (43-46;46-49).  Each veteran completed this screening survey upon entry 
into the VACS study.  In the PHQ-9, each of 9 DSM-IV criteria was rated by the veteran 
as “0” (not at all) to “3” (nearly every day).  As designated by Kroenke et al, veterans 
were considered to screen positive for MDD and were included in our sample if they had 
a total score greater than or equal to 10 (44).  This cutoff point conferred 88% sensitivity 
and 88% specificity for the formal diagnosis of MDD (44).  This simple scoring method 
was developed by Kroenke et al to optimize use of the PHQ-9 in a primary care setting 
without special training (44).  While it was preferable to have a formal diagnosis of 




means of making the diagnosis of depression, we had no reason to believe that the 
relative proportion of individuals with true depression among those testing positive with 
the screen would vary by HIV status.  Thus, the relative comparison between those in 
HIV care and those in general medical care still should be valid.  Veterans with PHQ-9 
scores consistent with minor depression and dysthymia had less clear diagnostic criteria 
and treatment recommendations and were not addressed in this study. 
 
Outcomes 
Depression treatment was defined as receipt of an SSRI or visit to mental health clinic in 
the 6 months prior to or following the survey.  The time frame was considered a 
reasonable window in which providers should respond to active depressive symptoms, 
including treatment initiated before the veteran was enrolled in the study.  To clarify the 
analysis, this study focused on provision of treatment, as evidence that the provider 
responded appropriately to active depressive symptoms.  We did not consider treatment 
effectiveness.  We did not distinguish the source of the prescription, either from 
generalist or specialist.  We considered at least one receipt of one prescription for SSRI 
or one visit to a mental health provider to indicate treatment.  We included the following 







   
We collected data on receipt of SSRI, date of last fill and dose per day.  Dichotomous 




SSRI.  A similar dichotomous variable was created for mental health service utilization 
with information gathered from the EMR. 
Previous studies have demonstrated that 98-100% of VA veterans get their 
prescription medication from the VA outpatient pharmacies because they have very low 
co-pays and, thus, strong financial incentives (10).  Of the VACS sample, 96% of 
enrolled HIV-infected veterans reported getting all of their HAART medication from VA 
pharmacies (39).  Thus, it is not unreasonable to assume that if the eligible veterans 
received an SSRI from any VA provider within the time frame, we would detect this 
prescription via the pharmacy database.  Likewise, because the VA is a nearly closed 
system, it is likely that any mental health utilization made for eligible veterans would also 
be documented via VA administrative data and detected by our data search. 
 
Mental Health Professional in Clinic 
A unique contribution of this thesis project to VACS data was a survey of clinic directors 
to determine their access to mental health providers.  Each of the 8 VACS sites was 
polled to see if they had a mental health care provider on-site in their general medicine 
and infectious disease clinics.  We defined mental health care provider as any individual 
specially-trained and designated via job description to screen and/or treat veterans 
identified by their PCP as having a mental health disorder.  These individuals could be 
social workers, registered nurses, nurse practitioners, physician assistants, psychologists 
or psychiatrists.  These survey items were collected in order to help account for 
individual clinic and site variation in depression treatment rates.  Clinic directors 
responded with information, including names, titles, contact information and descriptive 






To test our first hypothesis, the proportion of the sample with PHQ-9 depression was 
assessed, in total and by clinic type.  Bivariate comparisons by clinic were assessed using 
chi-square and t-tests.    The proportion of depressed veterans receiving SSRI was 
determined.  Bivariate correlates of lack of SSRI among depressed patients were assessed 
by HIV status, veteran demographics and medical comorbidities, site and individual 
clinic.   
Each of the individual survey items in PHQ-9 were separately analyzed by clinic 
status.  They were first assessed by survey item and severity measures.  Then, severity 
measures “0 – Not at all” through “2 – More than ½ the days” were grouped as “Other” 
and compared to severity measure “3 – Nearly every day” by clinic status to determine 
distribution of symptom severity. 
Site variation was assessed by clinic type and individual clinic and compared to 
bivariate data from mental health provider survey.  
Logistic regression was used to determine whether clinic type was associated with 
treatment, adjusting for potential confounding variables.  In both models, we controlled 
for the following demographic and clinical factors: age (<50 or ≥50), race (African-
American, White, non-Hispanic, Hispanic), medical comorbidities (alcohol and substance 
abuse/dependence, coronary artery disease, diabetes mellitus, hypertension and 
pulmonary disorders), clinic type (general medicine or infectious disease), geographic 
site (each of the 8 VACS sites) and individual clinic (each clinic at each geographic site).  
Logistic regression models were run using receipt of SSRI alone, and then receipt of 




controlled for clustering of multiple patients within a provider by using generalized 
estimating equations (GEE).  All statistical analyses were done using SAS version 9. 
 
Collaborators 
With the exception of the mental health provider survey, data for this project was taken 
from Dr. Justice’s ongoing VACS study.  Drs. Amy Justice and Joseph Goulet and Ms. 
Sueoka collaborated on project design.  Dr. Joseph Goulet conducted the statistical 
analysis.  Ms. Sueoka collaborated with Drs. Justice and Goulet on data presentation and 







The analytic sample consisted of 732 male veterans with a PHQ-9 score of 10 or greater.  
The sample had a median age of 48 years and 59% of the population was over age 50.  
The sample was predominantly African American (58%), with the rest of the population 
comprised of 36% white, non-Hispanic and 12% Hispanic (Table 3).  A minority of the 
veterans were married (20%) compared to those never married (29%), divorced (29%), 
separated (12%), widowed (3%), living with partner (8%).  Within this population, 40% 
had been diagnosed with alcohol abuse or dependence ever during the time period they 














   
AgeA   
≥50 years 40.9 39.6 41.7 0.6
   
RaceA   
Native American 4.6 3.4 5.5 0.2
Asian 0 0 0 
African-American 58.3 56.4 59.7 
Native Hawaiian or API 0.8 0.7 0.9 
White, non-Hispanic 35.8 37.6 34.6 
White, Hispanic 12.0 10.7 12.9 
   
Marital StatusA   
Married 20.0 32.2 11.5 <0.0001
Divorced 28.6 30.5 27.2 
Separated 11.9 14.4 10.1 
Widowed 2.9 1.7 3.7 
   
Number of Medical Diseases (median) B,C 2 (0-17) 2 (0-10) 3 (0-17) 0.1
Number of Comorbid Medical Diseases (mean) B,C 2.89 2.39 2.85 0.009
   
Receipt of SSRID 36.2 34.2 37.6 0.4
Mental Health Visit 28.3 32.6 25.4 0.03
Receipt of SSRI or Mental Health VisitB,D 48.1 48.9 47.7 0.8
Mental Health Visits (median)B 0 (0-126) 0 (0-126) 0 (0-45) 0.03
Mental Health Visits (mean)B 2.3 3.2 1.7 0.005
  
A Veterans Health Survey 
B VA Administrative Data 
C For HIV-infected population, HIV diagnosis not included in Number of Comorbid Medical Diseases 
D VA Pharmacy Benefits Management (PBM) 
 
Our sample was divided by clinic status into 59% HIV-infected veterans (n=434) 
and 41% uninfected veterans (n=298).  There were no significant differences by provider 
type in veteran age or race.  HIV-infected veterans were significantly more likely to have 
never married (22% vs. 6%, p<0.01).  In terms of medical comorbidities, uninfected 
veterans had significantly more cardiovascular and endocrine comorbidities, with no 
difference in rates of substance abuse/dependence and lung disease (Table 4).  The rates 




substance abuse/dependence (45% uninfected and 49% HIV-infected, p=0.4) were not 
statistically different.  There was no significant difference in rates of pulmonary diseases 
(20% vs. 22%, p=0.5).  On the other hand, 20% of uninfected veterans were diagnosed 
with coronary artery disease, compared to 9% of HIV-infected veterans (p<0.01).  
Likewise, the uninfected population had a higher prevalence of diabetes mellitus and 
hypertension than the HIV-infected population (29% vs. 17%, p<0.01, and 64% vs. 38%, 
p<0.01, respectively).  
For the HIV-infected population, we estimated the sample’s HIV severity by 
considering several clinical characteristics.  The median CD4 count was 338 (SD 285.5).  
The median viral load within this HIV-infected population was 2836 (SD 127,705.8). 
 
 











Alcohol abuse/dependence 40.2 37.3 42.2 0.2
Substance abuse/dependence 47.4 45.3 48.9 0.3
Coronary Artery Disease 13.8 20.1 9.2 <.0001
Diabetes mellitus 21.5 28.5 16.6 0.0001
Hypertension 48.9 64.4 38.3 <0.0001
Pulmonary Disorder 20.9 19.8 21.7 0.5
  
 
A ICD-9 diagnostic codes for comorbidities included in these categories detailed in Methods section.  
Includes ICD-9 diagnostic codes assigned to a veteran during the entire time he received care at a VHA, not 
just during the one-year study period.  
 
 
Prevalence of Active Depressive Symptoms 
 All 732 patients screened positive for depression, with 88% sensitivity and 
specificity for major depressive disorder.  Each of the PHQ-9 survey items were analyzed 




neurovegetative symptoms (Table 5) 1.  When considering each survey items by severity 
measure, there were significant differences between HIV-infected and uninfected 
veterans in levels of low self-esteem (survey item 6) and psychomotor changes (survey 
item 8).  Fifty-one percent of uninfected veterans reported that they felt low self-esteem 
nearly every day compared to 31.1% of the HIV-infected veterans (p<0.0001).   
Uninfected veterans were more likely to report psychomotor changes nearly every day 
(19.8% vs. 11.8, p=0.02), whereas HIV-infected veterans were more likely to report only 
occasional changes (25.1% vs. 19.5%, p=0.02).  There was no significant difference in 
frequency of the other 7 survey items by HIV status.  This analysis reflects the more 
severe depression in the uninfected veteran sample that was apparent from the overall 
screening and diagnostic categories.  In particular, uninfected veterans reported frequent 
cognitive-affective symptoms (low self-esteem) and neurovegetative symptoms 
(psychomotor change). 
 
                                                 
1 In Table 5, each bracketed term referred to a depressive symptom, either cognitive-affective or 
neurovegetative, categorized in Table 2.  Each term directly corresponds to DSM-IV criteria for major 





Table 5.  PHQ-9 Symptom Severity by Clinici. 
Symptom/Severity Items % Total (n=732) % HIV-(n=298) %HIV+(n=434) P 
1. [Anhedonia]  Little interest or pleasure in doing things A  
 Not at all 9.4 10.1 9.0 0.8
 Several days 27.0 26.2 27.4 
 > ½ the days 30.6 29.2 31.6 
 Nearly every day 33.1 34.6 32.0 
2. [Depressed Mood]  Feeling down, depressed, or hopeless  
 Not at all 5.6 4.0 6.7 0.08
 Several days 24.6 21.1 27.0 
 > ½ the days 32.4 33.6 31.6 
 Nearly every day 37.4 41.3 34.8 
3. [Sleep Change]  Trouble falling/staying asleep, sleeping too much   
 Not at all 7.1 8.4 6.2 0.2
 Several days 15.2 16.8 14.1 
 > ½ the days 27.9 24.2 30.4 
 Nearly every day 49.9 50.7 49.3 
4. [Fatigue]  Feeling tired or having little energy   
 Not at all 4.0 4.4 3.7 0.8
 Several days 15.3 16.1 14.8 
 > ½ the days 31.6 32.2 31.1 
 Nearly every day 49.2 47.3 50.5 
5. [Appetite Change]  Poor appetite or overeating   
 Not at all 20.1 24.2 17.3 0.1
 Several days 22.1 21.1 22.8 
 > ½ the days 28.4 25.5 30.4 
 Nearly every day 29.4 29.2 29.5 
6. [Low Self-esteem]  Feeling bad about yourself – or that you are a failure or have let 
yourself or your family down  
 Not at all 13.7 10.7 5.7 <.0001
 Several days 19.7 14.8 23.0 
 > ½ the days 27.5 23.5 30.2 
 Nearly every day 39.2 51.0 31.1 
7. [Concentration Difficulty]  Trouble concentrating on things, such as reading the newspaper 
or watching television  
 Not at all 22.1 20.8 23.0 0.2
 Several days 23.6 20.8 25.6 
 > ½ the days 25.6 25.5 25.6 
 Nearly every day 28.7 32.9 25.8 
8. [Psychomotor Change]  Moving or speaking so slowly that other people could have 
noticed. Or…being so fidgeting or restless that you have been moving around a lot... 
 Not at all 44.1 43.3 44.7 0.02
 Several days 22.8 19.5 25.1 
 > ½ the days 18.0 17.5 18.4 
 Nearly every day 15.0 19.8 11.8 
9.[Suicidality] Thoughts that you would be better off dead or of hurting yourself in some way 
 Not at all 49.9 45.3 53.0 0.2
 Several days 26.6 28.9 25.1 
 > ½ the days 12.3 12.4 12.2 





 Survey items were analyzed a second time, stratifying answer choices by “nearly 
every day” or “other” (which included “not at all,” “several days” and “more than half of 
the days”) (Figure 2).  Similar to the non-stratified analysis, this analysis showed 
prominent low self esteem in the uninfected veteran sample.  Uninfected veterans were 
more likely to feel low self esteem almost every day (51% vs. 31.1%, p<0.0001).  
Uninfected veterans were also more likely to have severe concentration disturbances 
(32.9% vs. 25.8%, p=0.04) and psychomotor changes (19.8% vs. 11.8%, p=0.003).   
Thus, the analyses reveal that uninfected veterans are more likely to have severe 
symptoms, especially those of low self esteem, concentration difficulties and 
psychomotor changes.  More than half of the uninfected veterans reported feeling low 
self esteem nearly every day.  Uninfected veterans had a greater proportion, nearing 
statistical significance, who reported depressed mood (uninfected 41% vs. HIV-infected 












































































  *   p<0.0001
  †   p=0.04









A Symptom Items 1-9 refer to the survey item numbers, detailed in Table 5. 
Item 1 – Anhedonia 
Item 2 – Depressed mood 
Item 3 – Sleep change 
Item 4 – Fatigue 
Item 5 – Appetite change 
Item 6 – Low self-esteem 
Item 7 – Concentration difficulty 
Item 8 – Psychomotor change 




In total, 36.2% of veterans received SSRIs within the one-year time frame (Table 3, 6).  
There was no significant difference between the total number of veterans receiving SSRIs 
by clinic status (34.2% of uninfected vs. 37.6% of HIV-infected, p=0.4).  Uninfected 
veterans were significantly more likely to receive mental health services only for 
depression treatment (32.6% of uninfected vs. 25.4% HIV-infected received any mental 
health service, p=0.03) (Table 6).  However, there was no significant difference by HIV 




(48.9% of uninfected vs. 47.7% of HIV-infected veterans, p=0.8).  Regarding race, 
African-American veterans were significantly less likely to have received SSRI (48% vs. 
30%, p<0.01).  Age and marital status also did not affect proportion of veterans receiving 
SSRIs.  Thus, in unadjusted analysis, there are no difference in rate of depression 









Although there were no significant differences in receipt of SSRI by HIV status, veteran 
demographics or comorbidities, there was significant site and clinic variation (Table 6).  
The proportion of treated veterans ranged from 20% at Site F to 50% at Site G (p=0.004). 
To consider different infrastructures for mental health care, clinic directors were 
surveyed regarding the presence of a mental health provider on site (Table 6).  The sites 
with the both the lowest and highest treatment rates had mental health providers in their 
clinics.  Patients receiving care in facilities with mental health providers were not more 
likely to have received SSRI (39.3% vs. 34.2%, p=0.2) (Table 6).  However, patients at 
facilities with mental health providers were significantly more likely to have received 
SSRI or mental health utilization (57.5% vs. 42.1%, p<0.0001). 
 
 Multivariate Models  
After controlling for veteran age, race and number of comorbid conditions, HIV-infected 
veterans did not differ significantly in receipt of SSRI (Table 7).  Each site was compared 
to the site with the largest number of veterans, Site D, in order to make the statistical 
estimates more stable.  The only variables which made a significant difference were site 
and clinic.  Veterans at Site F were less than half as likely to receive depression treatment 






Table 7.  Multivariate Regression of the Association of Receipt of SSRI with Veteran 
Demographic and Clinical factors A 
 OR 95% CI P 
Receipt of SSRI     
 Age 0.99 0.97 1.02 0.6 
 African-American 0.69 0.32 1.48 0.3 
 White, non-Hispanic 1.86 0.88 3.92 0.1 
 Hispanic 0.65 0.35 1.21 0.2 
 Alcohol 
abuse/dependence 
1.08 0.71 1.63 0.7 
 Substance 
abuse/dependence 
1.48 0.97 2.26 0.07 
 Coronary Artery 
Disease 
0.95 0.58 1.55 0.8 
 Diabetes mellitus 1.45 0.97 2.18 0.07 
 Hypertension 1.21 0.84 1.75 0.3 
 Pulmonary disorder 1.05 0.71 1.57 0.8 
     
 Site A – ID Clinic 1.26 0.61 2.61 0.5 
 Site B – ID Clinic 0.89 0.36 2.20 0.8 
 Site C – ID Clinic 1.41 0.70 2.85 0.3 
 Site D – ID Clinic 0.96 0.44 2.10 0.9 
 Site E – ID Clinic 0.58 0.24 1.40 0.2 
 Site F – ID Clinic 1.37 0.61 3.09 0.5 
 Site G – ID Clinic 2.05 0.94 4.46 0.07 
 Site H – ID Clinic 1.54 0.38 6.23 0.5 
     
 Site A – GM Clinic 0.71 0.29 1.74 0.5 
 Site B – GM Clinic 0.84 0.29 2.44 0.8 
 Site D – GM Clinic 0.55 0.20 1.48 0.2 
 Site E – GM Clinic 0.52 0.20 1.31 0.2 
 Site F – GM Clinic 1.83 0.74 4.54 0.2 
 Site G – GM Clinic 1.19 0.55 2.58 0.7 
 Site H – GM Clinic 1.20 0.33 4.36 0.8 
A All sites compared to Site C – GM clinic (clinic with largest number of patients). 
 
In Table 8, when adjusting the model to account for either receipt of SSRI or 
mental health visit, more significant differences in treatment rates by race, site and clinic 
became apparent.  When including mental health visits, white non-Hispanic veterans 





Table 8.  Multivariate Regression of the Association of Receipt of SSRI or Mental 
Health Services Utilization with Veteran Demographic and Clinical Factors A 
 
 OR 95% CI P 
Receipt of SSRI or Mental Health Utilization    
 Age 0.99 0.97 1.01 0.5
 African-American 0.84 0.41 1.72 0.6
 White, non-Hispanic 2.17 1.06 4.42 0.03
 Hispanic 0.71 0.40 1.29 0.3
 Alcohol abuse/dependence 1.42 0.95 2.13 0.09
 Substance abuse/dependence 1.17 0.78 1.77 0.5
 Coronary Artery Disease 0.92 0.57 1.49 0.7
 Diabetes mellitus 1.35 0.90 2.02 0.1
 Hypertension 1.21 0.85 1.73 0.3
 Pulmonary disorder 1.08 0.73 1.59 0.7
    
 Site A – ID Clinic 0.89 0.44 1.81 0.8
 Site B – ID Clinic 0.62 0.26 1.47 0.3
 Site C – ID Clinic 1.08 0.54 2.15 0.8
 Site D – ID Clinic 1.22 0.57 2.60 0.6
 Site E – ID Clinic 0.43 0.19 0.97 0.04
 Site F – ID Clinic 1.16 0.53 2.56 0.7
 Site G – ID Clinic 2.16 0.99 4.72 0.05
 Site H – ID Clinic 1.21 0.29 5.00 0.8
    
 Site A – GM Clinic 0.50 0.21 1.17 0.1
 Site B – GM Clinic 1.01 0.38 2.71 1.0
 Site D – GM Clinic 0.77 0.31 1.94 0.6
 Site E – GM Clinic 0.48 0.20 1.13 0.09
 Site F – GM Clinic 1.46 0.59 3.58 0.4
 Site G – GM Clinic 1.74 0.81 3.74 0.2
 Site H – GM Clinic 1.38 0.36 5.33 0.6
A All sites compared to Site C – GM clinic (clinic with largest number of patients). 
 
 
Veterans at Site H were more likely to receive depression treatment (OR=1.86, 
95% CI 1.10, 3.16) (Table 8).  Veterans at Site F were still less likely to receive 




veterans were nearly twice as likely to receive depression treatment as veterans at Site D 
(OR=1.86, 95% CI 1.10, 3.16).  Veterans at the ID clinic at Site E were less than half as 







By evaluating the relationship between depression treatment rates and HIV status, we 
have reached four main conclusions: depression symptomatology significantly overlaps 
with chronic disease symptoms; provider comfort levels do not influence provider 
practice regarding depression treatment; race exerts a significant influence over treatment 
rates; and depression treatment rates varied most significantly by individual site. 
Our sample was well-matched in that none of the demographic factors were 
significantly different between the depressed HIV-infected and uninfected veterans.  In 
terms of comorbidities, HIV-infected veterans had a significantly higher mean number of 
comorbid medical illnesses, not including HIV.  Uninfected veterans had a higher 
proportion of coronary artery disease, hypertension and diabetes mellitus compared to the 
HIV-infected population.  It is likely these prevalent chronic medical illnesses which 
brought the relatively young, uninfected veteran population to regular care at the VA 
primary care clinics. 
 Consistent with our primary hypothesis, both of these populations had high rates 
of active depression symptoms compared to the general population.  The point prevalence 
of primary care patients with depression in the general population is 10-14% (8).  In the 
initial VACS sample, 19% of uninfected veterans and 21% of HIV-infected veterans 
screened positive for major depressive disorder, which was not significantly different by 
HIV status.  However, analysis by survey item (which correlated with specific DSM-IV 
criteria) by HIV status revealed that depressed uninfected veterans scored higher in 
depression symptom severity.  Uninfected veterans had a significantly larger proportion 




reported higher rates of both cognitive-affective and neurovegetative symptoms: low self-
esteem (survey item 6), concentration (survey item 7) and psychomotor changes (survey 
item 8).  The only depressive symptom displayed more often by HIV-infected veterans 
was a neurovegetative symptom – appetite change – which is a common side effect of 
antiretroviral drugs.  In particular, the number of uninfected veterans who experienced 
daily low self-esteem was alarmingly high.  We expected higher rates of low self-esteem 
in the HIV-infected cohort secondary to HIV stigma (50;51). 
In opposition to our primary hypothesis, our results demonstrated no difference in 
depression treatment rates between veterans by HIV status.  Although a previous study 
reported substantial differences in general medicine versus infectious disease provider 
comfort with depression treatment, both uninfected and HIV-infected veterans were 
equally unlikely to be treated for depressive symptoms.  This overall low rate of 
treatment, ranging from 34-49%, suggests that comfort with treatment does not insure 
treatment among those with active depressive symptoms.  Depressed uninfected veterans 
had an equally low chance of being treated by their general PCP compared to depressed 
HIV-infected veterans receiving care from an HIV PCP.   
The presence of specific medical comorbidities did not have any effect on 
treatment status in this population.  With low overall treatment rates in this sample, we 
presumed that chronically-ill veterans would be least likely to be treated.  Chronic 
medical illnesses that affect global functioning and quality-of-life, such as cardiovascular 
disease, pulmonary disease and diabetes, are associated with a higher degree of frailty 
(6).  Veterans with these illnesses should have higher risks associated with depression 
treatment due to polypharmacy and compromised organ function (6).  Yet, there was no 




treatment in our sample.  Perhaps the number, and not the nature of comorbidities affects 
the receipt of depression treatment.  Indeed, higher numbers of comorbid medical illness 
have been associated with similar depression treatment rates but poorer depression 
outcomes (52;53).  
Our analysis of demographic and clinical factors revealed differences in treatment 
patterns by race.  While African-American veterans were equally as likely to be 
depressed in our sample, they were less likely to receive an SSRI.  There was no 
significant difference between races regarding SSRI treatment alone.  However, white, 
non-Hispanic patients were more likely to receive depression treatment when including 
mental health services in our treatment definition.   
In this sample, there is no clear reason why African-American veterans were 
significantly less likely to receive an SSRI than other racial/ethnic groups.  Both groups 
had access to health care as evidenced by their participation in the study.  They had the 
same reduced medication costs at the VA pharmacy.  Beyond cost, some recent studies 
suggest that ethnic minorities, such as African-Americans and Hispanics, are less likely 
to accept antidepressants as first-line treatment for depression from PCPs (54;55).   
It appears that it is not only “who you are,” but “where you are” that determines 
your likelihood of receiving depression treatment.  Our study demonstrated a high degree 
of individual clinic variation.  Patients were half as likely to receive depression treatment 
at one site, Site E – ID Clinic, than patients at the largest individual clinic, Site C – GM 
clinic.  They were twice as likely to receive depression treatment at Site G – ID Clinic, as 
patients at the largest individual clinic.  Again, clinic type (ID vs. GM) did not correlate 
with depression treatment rates.  Both the highest and lowest rates of treatment were both 




Patients receiving care in a clinic with mental health provider on site were 
significantly more likely to receive treatment when considering antidepressants or mental 
health care utilization (Table 6).  It is important to note that, as the VA is a closed system, 
these clinic sites are the locations where these veterans receive the majority of their 
health care.  Considering most VA general medicine and infectious disease clinics have 
similar designs, these sites have a large degree of uniformity.  We compared clinics of 
various sizes, ranging from 22 to 146 patients, but the VA clinics were all located in 
urban centers and served populations with similar demographics.  Site uniformity is 
valuable because it narrows our search for variables that could explain differences in 
depression treatment rates.  However, even at VA clinics, there are site differences in 
race/ethnicity composition, regional and institutional culture, and clinic infrastructure and 
provider characteristics that can affect health care quality.       
 
Study Limitations 
Potential limitations of this study include its cross-sectional design, basis on screening 
and narrow treatment definition.  First, this study was designed as a cross-sectional 
quantitative data analysis.  Our study would certainly benefit from the ability to follow up 
with these veterans to evaluate duration of symptoms and receipt of medication over 
time. 
Our depressed veterans did not carry a formal diagnosis of depression.  Instead, 
we used a screening tool, the PHQ-9, which was based on DSM-IV criteria.  The PHQ-9 
has demonstrated good correlation with MDD diagnosis in several clinical trials (43-
46;46-49).  However, the potential overlap of neurovegetative symptoms and chronic 




able to formally diagnose patients with MDD as part of our study.  It is possible that the 
PHQ-9 gives us a large number of false positives, which in turn would show inaccurately 
high rates of depression and low rates of treatment.  Moreover, we did not have the 
resources to rule out mania symptoms in patients with active depressive symptoms to 
verify that antidepressant therapy, and not a mood stabilizer, was the appropriate first-line 
treatment (19). 
However, it is a strength of our study that we did not depend on usual care 
depression diagnosis to determine our sample.  By using results from a uniformly-applied 
screening tool conducted at time of study enrollment, we were able to include all patients 
who had active depressive symptoms.  We included veterans who were depressed but not 
yet diagnosed by their provider. 
By narrowing our definition of depression treatment, we could have potentially 
biased our results to show inaccurately low treatment rates.  Our analysis did not include 
any veterans who received treatment, either prescription medication or counseling, 
outside the VA health care system.  We excluded veterans on classes of antidepressants 
other than SSRIs, but these exclusion criteria should not have biased this particular 
sample.  No veterans were excluded exclusively for MAOI use, and only a small number 
of veterans were excluded for TCA use. 
By excluding patients with PHQ-9 score lower than 10, we did not explore the 
potential subgroup of patients within the VACS sample who have been diagnosed with 
depression and adequately treated.  These patients would have PHQ-9 scores lower than 
10 as a result of successful treatment; thus, they would not be included in our analysis.  In 
this sense, our reported treatment rates may be lower than the true rates of depression 




depression prevalence.  It also should not affect our comparison of depression treatment 
rates by HIV status.   
 Our study considers only prevalence of depression treatment and not treatment 
effectiveness.  Many clinical trials have demonstrated that depression treatment is often 
ineffective.  It would have been clinically valuable to use serial PHQ-9 scores in this 
sample to track veterans’ depressive symptoms over time to assess remission rates.    
Moreover, it would be valuable to know the degree to which patient refusal contributed to 
low treatment rates.  This information would help us to apply our results to improve 
clinical practice. 
 
Agreement with Published Literature 
In populations with specific comorbid illnesss, similarly high rates of depression have 
been documented.  Current depression prevalence rates are 10-14% for patients receiving 
medical care in a primary care setting (8).  Depression prevalence rates are often higher 
in patients with specific medical illnesss: congestive heart failure (10-25%), diabetes (11-
15%), stroke (15-25%) and cancer (6-39%) (8).  HIV-infected patients have likewise 
been shown to have higher rates of depression compared to uninfected samples (28).  In 
veteran populations, Liu et al found that as many as 45% of their sample had severe 
depressive symptomatology (10).  They studied a similar veteran population at multiple 
geographic centers, but in an older sample, with a median age of 61 years.  Kilbourne et 
al reported even higher rates of depression in a group of HIV-infected veterans with 
comorbid depression (31).  Their sample had a higher proportion of veterans with 
depressive symptoms compared to general population estimates, with 46% reporting 




the veterans in our sample, these subjects had high rates of depression in the setting of 
chronic medical illness. 
Several other studies have reported comparably low depression treatment rates.  
Of the veterans with depressive symptoms in the study by Liu et al, 25% were 
appropriately diagnosed and started on antidepressant therapy (10).  Thus, this study 
reported high rates of depression and low rates of treatment comparable to the results of 
our analysis.  Koike et al reported no difference in treatment rates of patients with and 
without significant medical comorbidities.  Moreover, they followed their subjects 
longitudinally and reported worse depression outcomes in the patient group with 
comorbid medical illness (52;53). 
Our results agree with a large body of published studies which report racial/ethnic 
differences in depression treatment rates.  These studies have documented lower 
treatment rates, both for antidepressant therapy and counseling, for African-Americans 
compared to White, non-Hispanic patients (56-59).  These differences may be explained 
by racial differences in health care access or patient preference.  Health care access is less 
relevant to our patient population, as described earlier.  In our sample, patient preference 
may help to explain lower depression treatment rates.  The HIV Cost and Services 
Utilization Study (HCSUS) found that whites were much more likely than African-
Americans to accept medication as treatment for psychological problems such as 
depression (60).  In fact, African-Americans mounted greater resistance to formal 
depression treatment in any form (55).  Patients in these studies have listed a number of 
reasons, including fear of addictive qualities of medications and greater belief in non-




There is less evidence specifically identifying site variation and its effect on 
depression treatment rates.  However, a recent study by Virnig et al implicated both race 
and geography in quality of medical care (61).  Another study explored the role of 
individual clinic racial demographics on depression treatment rates for Latinos (62).  
Katon et al examined an even smaller microenvironment, looking at individual providers 
and differences in their depression treatment patterns (63).  This study did not find any 
significant difference in depression treatment patterns across 63 family practice 
physicians in 4 different primary care clinics (63).  These studies attempt to characterize 
the significant role of clinic environment on depression treatment. 
 
Our findings reinforce our current understanding that depression is poorly 
recognized and treated regardless of provider specialty and comfort level.  HIV status and 
patient comorbidities did not affect treatment rates in this sample.  However, race and site 
variation were significantly associated with receipt of treatment.  Our results emphasize 
the subtle complexities of depression in patients with comorbid medical illness. 
 
Current Depression Diagnostic Criteria Are Unclear In Specific Populations 
Predominant neurovegetative symptoms in our depressed, chronically-ill sample question 
if our screening tools distinguish between depression and chronic medical illness.  
Although the PHQ-9 has been validated as a sensitive and specific screening tool, it may 
overdiagnose depression in populations with chronic medical illness (43-46;46-49).  The 
PHQ-9 is based closely on DSM-IV criteria, which includes five neurovegetative items: 
sleep change, fatigue, appetite change, concentration difficulty and psychomotor change 




which symptoms stem from which disease process.  Patients may feel “slow” from poor 
lung function secondary to their COPD or “restless” from one of their medications.  In 
HIV-infected patients, concentration difficulties could stem from HIV-associated 
dementia or HIV1-associated minor cognitive motor disorder (6).  Clinical distinction 
between depressive symptoms and somatic symptoms become even less clear in 
advanced stages of medical disease, like HIV or cardiovascular disease (6;8;31). 
Even the formal diagnostic criteria for depression do not give clear guidance on 
how to distinguish between somatic and psychiatric symptoms.  The DSM-IV specifies 
that to achieve a formal MDD diagnosis, an individual must report active depressive 
symptoms that are “not due to the direct physiological effects of a substance (e.g., a drug 
of abuse, a medication) or a general medical condition (e.g., hypothyroidism)” (32). 
 These diagnostic complexities are especially salient in our chronically-ill sample.  
When we considered each of the survey items individually, we found that only about one-
third of both HIV-infected and uninfected veterans reported core depressive symptoms: 
anhedonia and depressed mood.  This is a low proportion considering that all of these 
patients screened positive for major depressive disorder.  Moreover, approximately half 
of both patient groups reported frequent neurovegetative symptoms.  Uninfected veterans 
surprisingly had a higher proportion of persistent cognitive-affective and 
neurodegenerative symptoms.  On the contrary, HIV-infected patients reported a higher 
rate of neurovegetative symptoms and only occasional cognitive-affective symptoms. 
In a review of HIV and depression in primary care, Colibazzi et al discuss the 
challenge of diagnosing depression in HIV-infected patients (6).  They recommend that 
clinicians choose either an inclusive or exclusive diagnostic model for depression.  The 




symptom as a depression symptom in the absence of another clear etiology (6).  Colibazzi 
et al discuss exclusive models, which substitute additional cognitive-affective symptoms 
for neurovegetative symptoms when diagnosing depression in chronically ill patients (6).  
The authors advocate choosing either model based on what the clinician thinks will lead 
to the best outcome for each patient.   
Thus, these guidelines are unable to give clear guidance.  They underscore the 
difficulty in developing global depression guidelines, and concede that a clinician might 
either overdiagnose or underdiagnose depression based on clinical judgment.  In their 
estimation, depression diagnosis and treatment relies more on the art of medicine in the 
absence of clear evidence.  Within the context of these guidelines, the HIV-infected 
veterans in our sample fall in the diagnostic “gray” zone.  It seems likely that if we took 
an exclusive approach to diagnosis, substituting cognitive-affective symptoms for 
neurovegetative ones, we would detect lower rates of screen-positive depression in our 
HIV-infected sample. 
Clinical studies have attempted to distinguish which symptoms come from which 
disease process in HIV-infected patients.  Kilbourne et al found that, in HIV-infected 
veterans with comorbid depression, neurovegetative symptoms were independently 
associated with the severity of their HIV-related illness, but not their depression severity 
(31).  This study concluded that neurovegetative symptoms may be attributed too often to 
depression.  Even commonly used HIV medications, such as antiretrovirals and 
prophylactic antibiotics, can cause neurovegetative symptoms like fatigue and appetite 
loss that can be mistaken for depression symptoms (6).  These researchers express 
concern that clinicians may misdiagnose depression in certain patients and actually fail to 





What Might Explain the Significant Site Variation? 
In seeking variables that affected receipt of depression treatment, we found significant 
differences at the level of the individual clinic.  Considering our samples were 
demographically well-matched, it is likely that these significant differences are related to 
clinic or provider variables.  Our “Mental Health Provider in Clinic” survey sought 
definitive differences in clinic infrastructure which could explain site variation of 
depression treatment rates.  We explored geographic proximity to mental health care 
services to see if it affected how many veterans received depression treatment.  Some 
clinics had mental health professionals located in GM and ID clinics to help PCPs 
diagnose and treat depression.  We detected a positive association between mental health 
professional in clinic and rates of depression treatment when we defined treatment as 
SSRI or mental health utilization.  Thus, it appears that lack of treatment may relate to 
proximity to mental health resources.  From our analysis, mental health providers on site 
in clinic have a positive effect on rates of depression treatment.  
The presence of opinion leaders at various sites could also account for clinic and 
site variation in depression treatment.  Clinical trials have demonstrated that opinion 
leaders, well-respected providers who informally influence colleagues’ clinical choices, 
can create significant differences in individual clinical practices (64-66).  For instance, if 
a well-respected physician at one VA site closely follows depression clinical research and 
quickly implements guidelines, then his colleagues are likely to adopt the same new 
guidelines.  The opposite behavior is also true; opinion leaders are often conservative and 
slow to adopt new guidelines or clinical practices (66).  Colleagues of these opinion 




opinion leaders are the variable that determines who receives depression treatment.  This 
knowledge could help us to create specific interventions to influence opinion leaders to 
recognize and treat depression.  
Researchers have adopted creative approaches to depression treatment in order to 
control for variables such as mental health provider access and opinion leaders.  They 
have placed their faith and funding into a variety of population-based models, to increase 
depression treatment rates in an affordable way, with modest results (3;4;14;15;67-71).  
Most of the current studies compare two different treatment models: referral and 
collaborative care models (3;4;14;15;67-71).  Referral care involves enhancing avenues 
for PCPs to refer patients to mental health specialists.  Mental health care occurs in a 
geographic site outside the primary care clinic.  In collaborative care models, adjunct 
staff – care managers and trained nurses – provides mental health care on-site at the 
primary care clinic.  Often, off-site psychiatrists oversee the mental health care decisions 
via weekly meetings. 
A recent study, IMPACT, has shown improved patient outcomes treating 
depression in elderly populations with multiple comorbid medical illnesses (53).  These 
results show promise because they demonstrate that patients with and without comorbid 
medical disease see comparable improvement in depressive symptoms.  Still, in the 
IMPACT study, the patients with comorbid illnesses had more severe depressive 
symptoms at baseline and after intervention than patients with depression but without 
medical comorbidity (53).  Even though they mounted a significant response to treatment, 






What Other Factors Affect Depression Treatment Rates in Chronically Ill Patients? 
Our study revealed associations between depression treatment and race and individual 
clinic, yet there are a myriad of other patient and provider considerations that weigh in on 
each treatment decision.  Depression treatment must start with a process of acceptance on 
the part of the patient.  Providers have reported significant patient resistance to starting 
depression treatment (72).  In order to accept treatment, the patient must first accept that 
there is a problem and that it is significant enough to require medical intervention.  If 
patients present with purely somatic symptoms, they often have trouble accepting that 
these symptoms are evidence of a mood disorder (73).  Many patients describe depression 
as a byproduct of weak willpower; likewise, they interpret depression treatment as 
evidence of character weakness (74). 
Even if they agree that they have a medical problem requiring medical treatment, 
many patients resist treatment because they feel stigmatized by being labeled with a 
psychiatric diagnosis (74;75).  Patients have reported lowered self-esteem when providers 
have attributed their distress to mental health illness, compared to “bodily illness” (74).    
As a result, mental illness stigma has a profound effect on patients’ willingness to accept 
depression diagnosis and treatment. 
Furthermore, patients may have practical barriers to completing depression 
treatment.  In order to complete acute depression treatment, most patients require at least 
6 to 8 weeks of antidepressant therapy or 4 to 20 weeks of psychotherapy (5).  Patients 
may have trouble with logistics, such as time, transportation or cost of these therapies.  
Patients have reported that factors such as unpaid time off work and insurance coverage  




 Providers may identify competing medical needs as a barrier to initiating 
depression treatment.  For many providers and patients, stabilization of medical illness is 
first priority during their outpatient visits (72).  Patients have “competing demands” that 
need to be addressed by their PCP (77;78).  A patient who has just been released from the 
hospital after a myocardial infarction or is starting insulin to optimize glycemic control 
may not wish to talk about initiating depression therapy in the same visit.  In this sense, it 
is important to consider whether unstable chronic medical illness competes with 
depression for medical attention.   
By discussing competing demands, we do not mean to justify lack of treatment.  
We simply discuss one potential explanation for the large proportion of patients who are 
depressed and untreated.  Many studies conclude that medical illnesses should be easier 
to treat if a provider first treats the patient’s depression (8;53).  Treating depression has 
been shown to improve patients’ medical outcomes with comorbidities such as 
congestive heart failure, diabetes and chronic obstructive pulmonary disease (8).  Many 
of these studies, however, focus on patients with one comorbid medical disease.  These 
results may not prove reproducible in a population such as our sample, which has 2.89 
median comorbid diseases. 
 
Much of the current literature concludes that patients go untreated because they 
do not have access to treatment, either at the provider or system level (72).  Indeed, one 
study describes the common belief that “poor performance by primary care physicians in 
detection and treatment of depression is the weak link in any national effort” (72).  Yet, 
our study highlights just a few of the innumerable factors that influence depression 




infrastructure, opinion leaders, patient acceptance of treatment and competing demands.  
Low depression rates probably result from a combination of all of these variables. 
In examining depression treatment rates, we have concluded that depression 
diagnostic criteria and screening tools have questionable validity in populations with 
comorbid medical illness.  We suspect that the high rates of depression reported in both 
HIV-infected and uninfected veterans are inaccurately high.  Perhaps a large number of 
patients who screen positive for depression do not truly have major depressive disorder 
and may not benefit from treatment.  Further outcome studies in patients with depression 
and chronic medical illnesses could help clinicians determine if they should choose 
inclusive or exclusive diagnostic models.  Clinicians could also benefit from studies 
which evaluate if a higher score threshold or substitution of cognitive-affective criteria in 
this population leads to more sensitive and specific screening tools. 
 In spite of these considerations, it is likely that depression is underdiagnosed and 
undertreated.  Our study focuses on a subpopulation, patients with multiple chronic 
medical illnesses, which may require more tailored interventions for depression.  Our 
current screening tools and treatment models may require modification for use in this 
population.  We have searched for variables that determine receipt of depression 
treatment in patients with comorbid medical disease.  For depression in our sample, it is 
clearly not a matter generalist or specialist quality of care or HIV status.  It is conceivable 
that opinion leaders, patient treatment preferences and patient competing demands all 
influence depression treatment rates.  In this case, collaborative care models and patient 
education programs may help to overcome these barriers to depression treatment.  It 
would be valuable to investigate both more rigorous depression interventions and 




certainly worthwhile to focus future research on this subpopulation because 95% of 
Medicare dollars are spent on patients with 2 or more chronic medical illness (35).   
Considering all of the various factors affecting depression treatment rates, it is 
likely that we will require a multifaceted approach to depression treatment in order to 
improve patient outcomes.  As the Veterans Health Administration serves the nation’s 
largest population of HIV-infected veterans and a large proportion of the nation’s 
chronically-ill patients, it will undoubtedly benefit from such improvements in depression 
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To Whom It May Concern: 
 
We would appreciate if you could answer this brief survey.  We are investigating rates of 
depression treatment of veterans at various VA sites participating in the Veterans Aging 
Cohort Study (VACS).  As part of this study, we would like to know if there is a 
collaborative model of care between medicine clinics and mental health clinics at your 
particular clinic. 
 
1. Do you have a mental health professional (MD, PA, APRN, RN) who has an 
office or sees patients in your clinic? 
a. Please circle one: Yes       or       No 
2. If you answered “yes” to question 1, will you please include the contact 
information (telephone number, email address and/or mailing address) for that 









Please return this survey as soon as possible to Faith Whitsett, at faith.whitsett@va.gov.  
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Table 6.  Difference in Treatment Rates by Site and by Presence of Mental Health Provider at Site. 
 Treatment Received – SSRI  
Treatment Received – SSRI or 
Mental Health Service  
Mental Health 













Yes No  
            
A  (n=117) 35.9 30.0 39.0  41.9 35.0 45.5   GM, ID 
B  (n=80) 42.5 46.9 39.6  52.5 56.3 50   GM, ID 
C  (n=66) 28.8 28.0 29.3  37.9 44.0 34.2   GM, ID 
D  (n=146) 41.8 38.3 44.2  52.1 51.7 52.3  ID GM 
E  (n=88) 38.2 27.6 33.9  52.3 48.3 54.2  GM, ID  
F  (n=98) 20.4 21.4 19.6  27.6 31.0 25.0   GM, ID 
G  (n=22) 50.0 50.0 50.0  63.6 66.7 60  GM, ID  
H  (n=115) 43.5 37.9 49.1  63.5 62.1 64.9  GM, ID  
           
Total Treated            
           
 SSRI alone 36.2 34.2 37.6 P=0.4     39.3 34.2 P=0.2 
            
 SSRI or Mental 
Health Service 
    48.1 48.9 47.7 P=0.8 57.5 42.1 P<0.0001 





    ID Clinic
Thank you for agreeing to participate in our study.  The following survey should take
about 40 minutes to complete.  Please answer all of the questions to the best of your
ability.  If you have any questions, please ask the Study Coordinator who gave you








g. Liver Disease or a bad liver or Cirrhosis
VACS PATIENT QUESTIONNAIRE - ID CLINIC
1. What is the name of your primary care provider in this clinic?
2. Has your doctor ever told you that you have any of the following?
k. Hypertension or high blood pressure
d. Congestive Heart Failure, also called weak heart or fluid on the lungs
b. Angina or Coronary Heart Disease
c. Heart Attack or Myocardial Infarction
o. Chronic lung disease (emphysema, asthma, chronic bronchitis
    or chronic obstructive lung disease)
x. Any kind of Cancer (please list below)
u. Depression
v. Post-Traumatic Stress Disorder
w. Schizophrenia (hearing voices or seeing things that others don't)
f. Diabetes or high blood sugar or "sugar"
p. Kidney Failure (or bad kidneys)
l. Pancreatitis
j. High cholesterol, lipids, or triglycerides
q. Stroke or "mini" stroke (Transient Ischemic Attack)
PRE-EXISTING CONDITIONS
YES NO
page 1 of 31
a. Anemia or "low blood"
e. Dementia or "Alzheimer's"
h. Hepatitis C
i. Chronic Hepatitis B
m. Bad nerves in your feet causing pain and numbness (neuropathy)
n. Bad circulation in your legs or feet
r. Pneumonia
s. Shingles
t. TB or Tuberculosis
v2.1
FOR ADMINISTRATIVE USE ONLY.  TO BE COMPLETED BY STUDY COORDINATOR.
Date of Visit: / / Study ID:
0428560656
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3. Has your doctor ever told you that you have any of the following? YES NO
a. Pneumocystis Pneumonia or PCP
b. Kaposi's Sarcoma or KS
c. Lymphoma (non Hodgkins)





i. Toxoplasmosis (in your head or brain)
j. Salmonella in your blood
k. CMV in your eye (retinitis) or in your blood (sepsis)
l. Severe weight loss due to your HIV infection
m. Problems thinking due to your HIV infection
n. Candida or fungus in your mouth or throat
HEALTH HABITS
4. How much do you weigh? (in pounds) (Fill in one circle)
90 lbs. or less
91 - 100 lbs.
101 - 110 lbs.
111 - 120 lbs.
121 - 130 lbs.
131 - 140 lbs.
141 - 150 lbs.
151 - 160 lbs.
161 - 170 lbs.
171 - 180 lbs.
181 - 190 lbs.
191 - 200 lbs.
201 - 210 lbs.
211 - 220 lbs.
221 - 230 lbs
231 - 240 lbs.
241 - 250 lbs.
251 - 260 lbs.
261 - 270 lbs.
271 - 280 lbs.
281 - 290 lbs.
291 - 300 lbs.
301 - 310 lbs.
311 - 320 lbs
321 lbs. or more
5. How tall are you without shoes on? (fill in feet (ft.) and inches (in.)) (If 1/2" please round up)
5 ft 00 in or less
5 ft 01 in
5 ft 02 in
5 ft 03 in
5 ft 04 in
5 ft 05 in
5 ft 06 in
5 ft 07 in
5 ft 08 in
5 ft 09 in
5 ft 10 in
5 ft 11 in
6 ft 00 in
6 ft 01 in
6 ft 02 in
6 ft 03 in or more
v2.1
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6. How often do you engage in regular activities (e.g. brisk walking, jogging, bicycling, etc.)
    long enough to work up a sweat?
NEVER
LESS THAN ONCE A WEEK
1 - 2 TIMES A WEEK
3 - 4 TIMES A WEEK














9. In the past 4 weeks, have you been without a permanent address that you call home?
YES
NO
10.Have you ever been without a permanent address that you call home?
YES
NO
11. In the past 4 weeks, have you stayed one or more nights
      in a shelter, on the street, in a park, or an abandoned building?
YES
NO
12. Have you ever stayed one or more nights in a shelter,
      on the street, in a park or an abandoned building?
YES
NO
v2.1 page 4 of 31
13. Do you now smoke cigars or pipes?
YES
NO
14. Do you now smoke cigarettes (i.e. within the last week)?
YES
NO
15. Have you ever smoked cigarettes for as long as a year?
YES (if YES answer a, b, & c below)
NO (if NO, skip to #16 on the next page)
a. How many years have you smoked/did you smoke cigarettes?
b. How many cigarettes do/did you smoke a day?
c. If you no longer smoke cigarettes, when did you quit?
LESS THAN 4 WEEKS AGO




16. Do you think HIV causes AIDS?
    NO, HIV
  DOES NOT
CAUSE AIDS
 I AM SURE




19. Have you ever had a drink containing alcohol?
YES (If YES, please continue)
NO, NEVER (If NO, skip to #53 on page 12)
20. When was the last time you had a drink?
IN THE LAST 30 DAYS
IN THE LAST 12 MONTHS
MORE THAN 12 MONTHS AGO
v2.1
17. When did you get your first HIV test that was positive?
Month Year
NEVER HAD A POSITIVE TEST
18. After you got your first positive HIV test result, how many months was it
 until you got medical care for HIV? Meaning more testing or an exam?
Months
21. When you are drinking, how often do you have a drink containing alcohol?
NEVER
MONTHLY OR LESS
2 TO 4 TIMES A MONTH
2 TO 3 TIMES A WEEK
4 OR MORE TIMES A WEEK
3874560654





DAILY OR ALMOST DAILY
24. Has a relative or friend or doctor or other health care worker been concerned
      about your drinking or suggested you cut down?
NO
YES, BUT NOT IN THE LAST YEAR
YES, DURING THE LAST YEAR













26. Here are a number of events that drinkers sometimes experience.
      Read each one carefully and complete the circle that indicates if this ever happened to you
      and how often it has happened to you during the past 3 months.
DAILY OR
 ALMOST





  A FEW
  TIMESNEVERNOYES
HAS THIS
    EVER
HAPPENED
  TO YOU?
DURING THE PAST 3 MONTHS, ABOUT HOW
OFTEN HAS THIS HAPPENED TO YOU?
a. I have been unhappy
    because of my drinking.
b. Because of my drinking,
    I have not eaten properly.
c. I have failed to do what is expected
of me because of my drinking.
d. I have felt guilty or ashamed
    because of my drinking.
e. I have taken foolish risks
    when I have been drinking.
f. When drinking, I have done
   impulsive things that I regret later.
g. My physical health has been
    harmed by my drinking.
h. I have had money problems
    because of my drinking.
i. My physical appearance has
   been harmed by my drinking.
j. My family has been hurt
   by my drinking.
k. A friendship or close relationship
has been damaged by my drinking.
l. My drinking has gotten in the
way of my growth as a person.
m. My drinking has damaged my
social life, popularity, or reputation.
n. I have spent too much or lost a lot
of money because of my drinking.
o. I have had an accident while
    drinking or intoxicated.
page 7of 31v2.1
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The following questions refer to any drinking of alcohol you have done in your lifetime.
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27. How much did you drink the last time you drank?
ENOUGH TO GET HIGH OR LESS
ENOUGH TO GET DRUNK
ENOUGH TO PASS OUT
28. Have you often had hangovers on Sunday or Monday mornings?
NO
YES




30. Have you gotten physically sick (e.g., vomit, stomach cramps) as a result of drinking?
NO
SOMETIMES
ALMOST EVERY TIME I DRINK
31. Have you had the "DTs" (delirium tremens) - that is, seen, felt or heard things not really there;
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35. Have you panicked because you feared you may not have a drink when you need it?
NO
YES





ALMOST EVERY TIME I DRINK
37. Have you carried a bottle with you or kept one close at hand?
NO
SOME OF THE TIME
MOST OF THE TIME
38. After a period of abstinence (not drinking), have you ended up drinking heavily again?
NO
SOMETIMES
ALMOST EVERY TIME I DRINK
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41. Do you drink throughout the day?
NO
YES
42. After drinking heavily, has your thinking been fuzzy or unclear?
NO
YES, BUT ONLY FOR A FEW HOURS
YES, FOR ONE OR TWO DAYS
YES, FOR MANY DAYS




44. Do you almost constantly think about drinking and alcohol?
NO
YES
















48. With respect to blackouts (loss of memory)
HAVE NEVER HAD A BLACKOUT
HAVE HAD BLACKOUTS THAT LAST LESS THAN AN HOUR
HAVE HAD BLACKOUTS THAT LAST FOR SEVERAL HOURS
HAVE HAD BLACKOUTS THAT LAST FOR A DAY OR MORE




50. Do you gulp drinks (drink quickly)?
NO
YES
51. After taking one or two drinks, can you usually stop?
NO
YES
52. Have you had any of the following symptoms in the last 12 months?
 Mark all that apply.  (Please note this question refers only to the last 12 months.)
THE SHAKES
BEING UNABLE TO SLEEP
FEELING VERY NERVOUS OR RESTLESS
SWEATING





SEEING OR HEARING THINGS THAT
OTHERS COULD NOT SEE OR HEAR
v2.1
5555560652
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53. For each of the following drugs, please mark the box that best indicates
      how often in the past year you used each drug.
EVERY
   DAY
  4 - 6
TIMES
    A
 WEEK
  1 - 3
TIMES
    A
 WEEK
  1 - 3
TIMES














    Hashish
b. Cocaine or
    Crack
c. Stimulants
    (amphetamines,
    uppers, speed,
    crank, crystal
    meth, bam)
d. Opioids (heroin,
    morphine,
    codeine, opium)
If you have used any of the drugs listed above, please answer questions 54 through 60;
if you have not used any of the drugs, please SKIP to question #61 on page 14.
54. In the past 12 months, did your use of drugs ever interfere with your
 work at school, or a job, or at home?
YES
NO
(If YES, please answer #54a)
54a. How often in the past 12 months did drugs interfere
   with your  work at school, or a job, or at home?
ONCE OR TWICE
BETWEEN 3 AND 5 TIMES
BETWEEN 6 AND 10 TIMES
BETWEEN 11 AND 20 TIMES
MORE THAN 20 TIMES
55. During the past 12 months, were you ever under the influence of a drug in a situation where you
could get hurt - like when driving a car or boat, using knives or guns or machinery, or anything else?
YES
NO
e.  Other (please specify):
v2.1
(If NO, please skip to #55)
6244560658
56. During the past 12 months, did you have any emotional or psychological problems from using
drugs - such as feeling uninterested in things, feeling depressed, suspicious of people,
paranoid, or having strange ideas?
YES
NO
57. During the past 12 months, did you have a strong desire or urge to use a drug
      that you could not keep from using it?
YES
NO
58. During the past 12 months, did you have a period of a month or more when you spent
      a great deal of time using drugs or getting over its/their effects?
YES
NO
59. During the past 12 months, did you ever use much larger amounts of drugs than you
      intended to or did you use it/them for a longer period of time than you intended to?
YES
NO
(If YES, please answer #59a)
59a. How often in the past 12 months, did you use a much larger amount of drugs than
   you intended to or use it/them for a longer period of time than you intended to?
ONCE OR TWICE
BETWEEN 3 AND 5 TIMES
BETWEEN 6 AND 10 TIMES
BETWEEN 11 AND 20 TIMES
MORE THAN 20 TIMES
60. During the past 12 months, was there ever a time when you had to use more
      of a drug than you used to get the same effect you wanted?
YES
NO
page 13 of 31v2.1
(If NO, please skip to #60)
9707560655
61. In order to compare our study with the results of other studies, we'd like to know if
you have ever done any of the following things.
Have you:
a. Had sex with a man?
b. Had sex with a woman?
c. Injected drugs?
d. Had sex with someone you know or believe
to have been an IV or injected drug user?
e. Had sex with someone you know or         
believe to have been bisexual?
f. Received clotting factor for hemophilia or
   other blood clotting disorder?
g. Received transfusion of blood components




The next questions are about your sexual behavior. By sex we mean oral, vaginal, or anal sex,
but NOT masturbation. When we talk about condoms, we mean both male as well as female
condoms.
62. During the past 12 months, have you had sex?
63. During the past 12 months, with how many people have you had sex?
64. During the past 12 months, have you had sex with only males, only females,
      or with both males and females?
ONLY MALES
ONLY FEMALES
BOTH MALES AND FEMALES
65. Thinking back about the last time you had sex, did you or your partner use a condom?





YES (If YES, please answer #63 - 66 below)
NO [If NO, skip to #67 on Next Page]
people




67. Have you ever, even once, used a needle to inject any drug?
      DO NOT include anything you took under a doctor's orders.
YES
NO [SKIP to #76 on the next page]
YES
NO [SKIP to #76 on the next page]
68. In the past 12 months, have you ever used a needle to inject any drug?
69. The last time that you used a needle to inject a  drug, what drug did you inject?






70. The last time you used a needle to inject a drug, was it a new sterile needle?







71. The last time you used a needle to inject a drug, did you use cottons, a cooker,
      or rinse water that you knew or suspected someone else had used before?
72. The last time you used a needle to inject a drug, did someone else use the needle after you?
73. The last time you used a needle to inject a drug, did someone else use the cottons,
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74. The last time you used a needle to inject a drug, did someone use their syringe to squirt the drug




75. The last time you used a needle to inject a drug, did you use your syringe to squirt the drug into




76. For each of the following statements, fill in the circle if you
 strongly agree, agree, disagree, or strongly disagree.
a. I want to take an active role in the medical
management of my disease and its complications
b. It is better to trust a doctor or nurse in
charge of a medical procedure than to
question what they are doing
c. I want to know as much as I can about the
medical aspects of my disease and treatment
d. I'd rather have doctors and nurses make
decisions about what's best rather than
for them to give me a lot of choices
STRONGLY
   AGREE AGREE DISAGREE
STRONGLY
 DISAGREE
SOCIAL ASPECTS OF HEALTH
77. How often do you see or hear from relatives or close friends? Would you say less than once a month,




     ONCE
 A MONTH MONTHLY
  A FEW
  TIMES
A WEEK
   A FEW
   TIMES
A MONTH DAILY
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78. How many close friends or family do you have with whom you feel at ease,







79. In response to having a medical illness, how often during the past four weeks have you
done each of the following? Would you say all of the time, most of the time, a good bit of the time,






   OF
  THE
  TIME
  A GOOD
   BIT OF
     THE





   LITTLE
      OF
     THE





i. Involved yourself in
   volunteer work or a
   community organization?
h. Tried to keep it from
    bothering you?
g. Talked to someone         
about how you were         
feeling about having it?
f. Tried to keep yourself
from worrying about it?
e. Criticized or
lectured yourself?
d. Asked other people for
    advice and information?
c. Kept yourself from         
thinking too much about it?
a. Used my situation to change
or grow as a person?




80. Are you an official member of a church or other place of worship?
YES
NO
81. How religious do you consider yourself?





82. During the past year, how often did you attend religious services?
NEVER
LESS THAN TWICE A YEAR
SEVERAL TIMES A YEAR
ABOUT ONCE A MONTH
TWO TO THREE TIMES A MONTH
EVERY WEEK
SEVERAL TIMES A WEEK
EVERYDAY
83. How frequently do you pray?
NEVER
LESS THAN TWICE A YEAR
SEVERAL TIMES A YEAR
ABOUT ONCE A MONTH
TWO TO THREE TIMES A MONTH
EVERY WEEK
SEVERAL TIMES A WEEK
EVERY DAY
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86. If you compare your life now to before HIV, would you say your life is:
BETTER NOW
WORSE NOW
ABOUT THE SAME AS BEFORE I KNEW I WAS HIV POSTIVE
DON'T KNOW





NOT AT ALL IMPORTANT
85. When you have problems or difficulties in your life,
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HEALTH CARE UTILIZATION
87. How many times have you used VA health care in the last 4 months?
a. For overnight stays in a hospital or nursing home
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15+
b. For outpatient care
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15+
9162149147




The following questions ask for your views about your regular doctor.
Your doctor will not be able to link your name to your responses.
89. Within the past 4 months, how many visits have you had with a
      mental health professional within the VA?
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15+
90. Within the past 4 months, how many visits have you had with a
      mental health professional outside the VA?
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15+
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88. How many times have you used health care outside the VA in the last 4 months?
a. For overnight stays in a hospital or nursing home
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15+
b. For outpatient care
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15+







94. Thinking about talking with your regular doctor, how would you rate the following?
 VERY
POOR POOR FAIR GOOD
VERY
GOOD EXCELLENT
c. Doctor's explanation of your problems
    or treatment that you need
b. Attention your doctor gives to
 what you have to say
a. Thoroughness of your doctor's
questions about your symptoms
and how you are feeling
95. Thinking about how well your regular doctor knows you, how would you rate







96. All things considered, how much do you trust your regular doctor?
1 2 3 4 5 6 7 8 9 10
NOT AT ALL COMPLETELY














99.Have any of the following been a problem for you in arranging for your medical care in the
last 12 months? If so, how much of a problem?
a. Difficulty receiving care you and
    your doctor believed necessary
b. Not being able to get a referral to a
    specialist that you wanted to see
    YES,
    A BIG
PROBLEM
    YES, A
     SMALL
 PROBLEM
     NO,
   NOT A
PROBLEM
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97. Do you know who to ask when you have questions about your care?
YES, ALWAYS
YES, SOMETIMES I DO
NO
DIDN'T HAVE ANY QUESTIONS
100. Overall, how would you rate the quality of care you received the past two months?
3883149141
103.  Most anti-HIV medications need to be taken on a schedule, such as "2 times a day,"
         or "3 times a day," or "every 8 hours."  How closely did you follow your specific 
         schedule over the last four days?
NEVER
SOME OF THE TIME
ABOUT HALF OF THE TIME
MOST OF THE TIME
ALL OF THE TIME
104. Did you miss any of your anti-HIV medication last weekend--last Saturday or Sunday?
YES
NO
105. When was the last time you missed any of your HIV medications?
WITHIN THE PAST WEEK
1 - 2 WEEKS AGO
2 - 4 WEEKS AGO
1 - 3  MONTHS AGO
OVER 3 MONTHS AGO
NEVER SKIPPED
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Most people with HIV have many pills to take at different times during the day, and find it hard to always
remember their pills.  Please tell us what you are doing.  Don't worry about telling us that you don't take
all your doses.  We need to know what is really happening, not what you think we "want to hear."
Please fill in the circle of the one response that best describes how you take your medications.
101. Do you take any medicine to treat your HIV infection?
YES (If YES, please answer #102 - 105 below)
NO (if NO, skip to #106 on the next page)
8560149148
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YES (If YES, please answer # 107 below)
NO (if NO, skip to #108)
106. Do you take any prescription medicine to treat other medical problems you may have?







108. The following questions ask about symptoms you might have had during the past four weeks.
         Please fill in the circle of the one response that best describes this symptom.
  I DO NOT
    HAVE
    THIS
SYMPTOM
        IT
   DOESN'T
BOTHER ME
 IT BOTHERS
      ME A
     LITTLE
I HAVE THIS SYMPTOM AND...
      IT
BOTHERS
     ME
       IT
BOTHERS
ME A LOT
a. Fatigue or loss of energy?
b. Fevers, chills, or sweats?
c. Feeling dizzy or light headed?
d. Pain, numbness, or tingling
    in the hands or feet?
e. Trouble remembering?
f. Nausea or vomiting?
g. Diarrhea or loose bowel         
movements?
h. Felt sad, down, or depressed?
i. Felt nervous or anxious?
j. Difficulty falling or
staying asleep?
6523149145
109. Do you think your symptoms are caused by the drugs you take to treat your HIV infection?
110. Do you think your symptoms are caused by drugs you take to treat other medical conditions?
YES NO
YES NO
k. Skin problems, such as
rash, dryness, or itching?
l. Cough or trouble catching
   your breath?
m. Headache?
n. Loss of appetite or change
    in the taste of food?
o. Bloating, pain, or gas
    in your stomach?
p. Muscle aches or joint pain?
q. Problems with having sex,
such as loss of interest or
 lack of satisfaction?
r. Changes in the way your body
looks, such as fat deposits
or weight gain?
s. Problems with weight
    loss or wasting?
t. Hair loss or changes in the
   way your hair looks?
UNSURE
UNSURE
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       IT
BOTHERS
ME A LOT
      IT
BOTHERS
     ME
 IT BOTHERS
      ME A
     LITTLE
        IT
   DOESN'T
BOTHER ME
  I DO NOT
    HAVE
    THIS
SYMPTOM
I HAVE THIS SYMPTOM AND...
1732149142




112. If you checked off any problem listed above, how difficult have these problems made it for
   you to do your work, take care of things at home, or get along with other people?
i. Thoughts that you would be better off dead
or of hurting yourself in some way
h. Moving or speaking so slowly that other         
people could have noticed. Or the opposite         
- being so fidgety or restless that you have         
been moving around a lot more than usual
g. Trouble concentrating on things, such as
    reading the newspaper or watching television
f. Feeling bad about yourself - or
that you are a  failure or have let
yourself or your family down
e. Poor appetite or overeating
d. Feeling tired or having little energy
c. Trouble falling/staying asleep,
sleeping too much
b. Feeling down, depressed, or hopeless
a. Little interest or pleasure in doing things
   NEARLY
EVERY DAY
SEVERAL
   DAYS
  NOT
AT ALL
111. Over the last 2 weeks, how often have you been bothered by any of the following problems?
QUALITY OF LIFE
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Questions 113a-g are from the Beck Depression Inventory®-II (BDI®-II). 
The BDI®-II is protected by federal copyright law.
a. Can you do heavy work at home, like scrubbing         
floors, lifting or moving heavy furniture?
b. Can you do moderate work at home like moving
a chair or table, or pushing a vacuum cleaner?
c. Can you do light work around the house
    like dusting or washing dishes?
d. If you want to, can you participate in active sports
such as swimming, tennis, basketball, volleyball
or rowing a boat?
e. If you want to, can you run a short distance?
f. Can you walk uphill or upstairs?
g. Can you walk a block or more?
h. Can you walk around inside the house?
i. Can you walk to a table for meals?
j. Can you dress yourself?
k. Can you eat without help?
l. Can you use the bathroom without help?
114. These questions are about any physical limitations you might have.
   For these activities, please indicate which response best describes you
   by darkening the circle under the appropriate response after each statement.
   YES,
  I CAN
DO THIS
     YES,
BUT ONLY
  SLOWLY
   NO, I
CANNOT
DO THIS
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These questions ask for your views about your health. This information will help keep track of how you
feel and how well you are able to do your usual activities. Please answer each question by filling in the
circle.  If you are unsure about how to answer, please give the best answer you can.








The following items are about activities you might do during a typical day.
Does your health now limit you in these activities? If so, how much?
    YES,
 LIMITED
A LITTLE
    YES,
 LIMITED




116. Moderate activities, such as moving a table, pushing
        a vacuum cleaner, bowling, or playing golf
117. Climbing several flights of stairs
During the past 4 weeks, have you had any of the following problems with
your work or other daily activities as a result of your physical health?
118. Accomplished less than you would like
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During the past 4 weeks, have you had any of the following problems with your work or other regular
daily activities as a result of any emotional problems (such as feeling depressed or anxious)?
120. Accomplished less than you would like
YES
NO
121. Didn't do work or other activities as carefully as usual
YES
NO
122. During the past 4 weeks, how much did pain interfere with your normal work








NEVER ATTENDED SCHOOL OR ONLY KINDERGARTEN
GRADES 1 THROUGH 8 (ELEMENTARY)
GRADES 9 THROUGH 11 (SOME HIGH SCHOOL)
HIGH SCHOOL GRADUATE
GED
COLLEGE 1 YEAR TO 3 YEARS (SOME COLLEGE OR TECHNICAL SCHOOL)
COLLEGE GRADUATE
GRADUATE SCHOOL
129. What is the highest grade or year of school you completed?
ALL OF THE TIME
MOST OF THE TIME
SOME OF THE TIME
A LITTLE OF THE TIME
NONE OF THE TIME
126. During the past 4 weeks, how much of the time has your physical health or emotional
   problems interfered with your social activities (like visiting with friends, relatives, etc.)?
DEMOGRAPHICS
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127. What is your date of birth?
month        day            year
v2.1
128.  What is your sex?
MALE
FEMALE
 These questions are about how you feel and how things have been with you during the past 4 weeks.
 For each question, please give the one answer that comes closest to the way you have been feeling.
 How much of the time during the past 4 weeks -













  OF THE




125. Have you felt downhearted
  and blue?
124. Did you have a lot of energy?
123. Have you felt calm
  and peaceful?
2146149142








LOOKING FOR WORK AND UNEMPLOYED FOR MORE THAN ONE YEAR





133. How many persons live in your household (including yourself)?
134. Are you currently...(mark all that apply)
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Thank you for completing our questionnaire.
Please return this to the Survey Coordinator who gave it to you.









130.  What is your race  (Mark one or more)?
AMERICAN INDIAN OR ALASKA NATIVE
ASIAN
BLACK OR AFRICAN AMERICAN
NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER
WHITE
131.  What is your ethnicity?
HISPANIC OR LATINO
NOT HISPANIC OR LATINO
2024149147
